{"entity":{"id":"stamford-pharmaceuticals","kind":"company","name":"Stamford Pharmaceuticals","aka":["Stamford Pharmaceuticals, Inc."],"tldr":"Stamford Pharmaceuticals injects a modified common-cold virus carrying an immune-signalling gene into skin cancers, and is testing it alongside a standard tablet for advanced basal cell carcinoma.","summary":"Stamford Pharmaceuticals, Inc., which moved its head office to Austin, Texas in 2023, is a clinical-stage oncology company developing gene therapies for skin and visceral cancers. SP-002 is an adenoviral vector (serotype 5) that delivers the gene for interferon gamma into the tumour. A phase 2 study tests SP-002 with the hedgehog pathway inhibitor vismodegib in locally advanced basal cell carcinoma (NCT06344052); the company plans a phase 2/3 study in high-risk nodular basal cell carcinoma in 2027 and has an open IND for cutaneous squamous cell carcinoma. Its SP-500 platform conjugates the vector with small-molecule payloads, with preclinical candidates for bladder, pancreatic, head and neck, prostate and breast cancer. Its first registered cancer trial, NCT06344052, was posted on ClinicalTrials.gov in April 2024; an earlier phase 2a study of SP-002 (NCT04416516) is registered under a different sponsor name.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://stamfordpharmaceuticals.com/"},{"label":"Product and pipeline","url":"https://stamfordpharmaceuticals.com/product-and-pipeline"}],"tags":[],"related":[],"cancers":["basal-cell-carcinoma"],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06344052"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website, product page and news list read on 29 October 2026. Founding year not stated. No financing round was read. The sponsor of NCT04416516 was not checked."],"hq":"Austin, TX","country":"US","companyType":"biotech","website":"https://stamfordpharmaceuticals.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/stamford-pharmaceuticals/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"trial":[{"id":"nct06344052","kind":"trial","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","route":"/trials/nct06344052/"}]}}